SGLT2-is may represent a valid option for the treatment of patients with HF in all the EF ranges (HFrEF, HFmrEF, HFpEF) and concomitant COPD as an additional treatment or, occasionally, as an alternative therapy for patients who are intolerant to β-blockers, as demonstrated in a study by Dewan and colleagues, which showed that dapagliflozin, an SGLT2-i, had a favorable effect in a population of patients with HFrEF and COPD [208,209]. The gene discussed is SLC5A2; the disease is hydrops fetalis.